Johnson & Johnson stock: Overbought signals and cautious trading drive mild pullback

Traders Union
All News
Financial News
Johnson & Johnson drops 0.41% today

Highlights

Johnson & Johnson will report fourth-quarter fiscal 2025 results before market open on January 21, with investor focus on new guidance and product developments.
The company continues its streak of quarterly dividend increases, currently paying $1.30 per share, and remains active in share buybacks.
Post-Kenvue restructuring is sharpening Johnson & Johnson's focus on medical technology and new drug development, supported by a strong balance sheet.

Earnings outlook and post-Kenvue focus drive investor positioning

Johnson & Johnson is set to release its fourth-quarter fiscal 2025 results before the market opens on January 21, drawing investor focus to upcoming guidance and developments in its drug and medical device divisions. The company continues its long-standing record of quarterly dividend increases, now paying $1.30 per share, and actively engages in share buybacks. Johnson & Johnson's post-Kenvue restructuring is strengthening its focus on medical technology and new drug development, supported by a strong balance sheet.

Overbought risk emerges amid strong technical trend signals

Technically, JNJ finds its nearest dynamic support at the Ichimoku Kijun level ($210.13), while resistance is closest near $220 and the MA-50 at $204.54. The MACD and ADX both indicate ongoing upward momentum, supported by positive Bull/Bear Power and a confirming Awesome Oscillator. However, several oscillators highlight elevated overbought risk: RSI is near 70, Stochastic RSI is deep in overbought at 91.66, and the CCI remains at extreme highs. Price action has softened intraday, with the stock trading near the lower end of today’s $218.16 – $220.08 range as sellers exert pressure after the open, revealing a divergence between strong trend signals and weakening short-term momentum.

Upside favored as technicals support breakout scenario

In the coming five trading days, JNJ is likely to move within a $215.00 – $222.50 volatility band relative to current levels. Technical signals on weekly timeframes suggest a strong probability — greater than 80% — of further upside, with robust support just above $210. A bullish breakout above $220 – $222 could extend gains further, while a decisive move below the Ichimoku Kijun ($210) would shift the outlook bearish and open a path toward $208.

Anton Kharitonov, analyst at Traders Union, sees Johnson & Johnson maintaining its bullish structure above key moving averages. However, he is skeptical about immediate upside due to clear overbought technicals and weakening intraday momentum. Any bullish case hinges on a breakout above $222, with a drop below $210 turning the picture negative. "Technically, the risk of a sharp pullback is significant here, so I remain cautious unless $210 holds firm."

Previously it was reported that Johnson & Johnson maintains strong bullish momentum, trading well above key moving averages with daily MACD and ADX indicators supporting ongoing buyer strength, while overbought signals from RSI and other oscillators suggest the stock is at risk of near-term consolidation. The price is currently supported by dynamic and moving average levels, with resistance near $223.00; the likelihood of further upside remains high, though a sustained break below support could prompt a short-term pullback.

Source of Data: JNJ Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.